San Francisco startup Framework Therapeutics can be focusing on an oral, after-day-to-day GLP-1 drug referred to as GSBR-1290—the drug surpassed Wall Road’s expectations in June any time a mid-phase examine showed normal weight loss of about six% and it strategies to start out One mo